J
Jae Cheol Lee
Researcher at Sungkyunkwan University
Publications - 111
Citations - 3438
Jae Cheol Lee is an academic researcher from Sungkyunkwan University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 30, co-authored 109 publications receiving 2707 citations. Previous affiliations of Jae Cheol Lee include Stanford University & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Jin Kyung Rho,Yun Jung Choi,Jin Kyung Lee,Baek-Yeol Ryoo,Im Il Na,Sung Hyun Yang,Cheol Hyeon Kim,Jae Cheol Lee +7 more
TL;DR: Induction of EMT may contribute to the decreased efficacy of therapy in primary and acquired resistance to gefitinib.
Journal ArticleDOI
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer
Kevin A. Kwei,Young Ho Kim,Luc Girard,Jessica Kao,Manuela Pacyna-Gengelbach,Keyan Salari,Jae Cheol Lee,Yoon-La Choi,Yoon-La Choi,Mitsuo Sato,Pei Wang,Tina Hernandez-Boussard,Adi F. Gazdar,Iver Petersen,John D. Minna,Jonathan R. Pollack +15 more
TL;DR: It is shown that small interfering RNA-mediated knockdown of TITF1 in lung cancer cell lines with amplification led to reduced cell proliferation, manifested by both decreased cell-cycle progression and increased apoptosis.
Journal ArticleDOI
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Jin Haeng Chung,Jin Kyung Rho,Xianhua Xu,Jong Seok Lee,Ho Il Yoon,Choon Taek Lee,Yun Jung Choi,Hye Ryoun Kim,Cheol Hyeon Kim,Jae Cheol Lee +9 more
TL;DR: It is found that EMT developed in a lung cancer patient who had an acquired resistance to erlotinib while there were no known resistant mechanisms such as T790M and MET amplification.
Journal ArticleDOI
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Mingxia Gu,Ning-Yi Shao,Silin Sa,Dan Li,Vittavat Termglinchan,Mohamed Ameen,Ioannis Karakikes,Gustavo Sosa,Fabian Grubert,Jae Cheol Lee,Aiqin Cao,Shalina Taylor,Yu Ma,Zhixin Zhao,James Chappell,Rizwan Hamid,Eric D. Austin,Joseph D. Gold,Joseph C. Wu,Michael Snyder,Marlene Rabinovitch +20 more
TL;DR: Comparison of induced pluripotent stem cell-derived endothelial cells from three families with unaffected mutation carriers, FPAH patients, and gender-matched controls identified features of UMC iPSC-ECs related to modifiers of BMPR2 signaling or to differentially expressed genes that could help inform development of future treatment strategies.
Journal ArticleDOI
Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.
Haodi Wu,Jae Cheol Lee,Ludovic G. Vincent,Qingtong Wang,Mingxia Gu,Feng Lan,Jared M. Churko,Karim Sallam,Elena Matsa,Arun Sharma,Joseph D. Gold,Adam J. Engler,Yang Kevin Xiang,Donald M. Bers,Joseph C. Wu +14 more
TL;DR: In this article, the β-adrenergic pathway was blunted in dilated cardiomyopathy (DCM) patients with a mutation in TNNT2, a sarcomeric protein.